- About Us
- Activities Calendar
- Capability & Capacity Development
- Media & Resources
Life Sciences Industry Group (LSIG) represents the pharmaceutical manufacturers and distributors. It comprises two sub-groups, Singapore Pharmaceutical Manufacturers’ Council (SPMC) and Singapore Pharmaceutical Trade Organisation (SPTO). The group was established to maintain and enhance the reputation and credibility of the pharmaceutical industry in Singapore. Members from SPTO and SPMC meet regularly with the Health Sciences Authority (HSA) to discuss the latest regulatory landscape in the region as well as challenges faced by local industry.
Life Sciences Industry Group (LSIG) promotes and facilitates the growth of the pharmaceutical industry in Singapore. It discusses and comments on regulatory issues affecting the industry besides co-ordinating and undertaking studies to identify new products and market opportunities.
Founded in 1986, SPMC represents a group of local manufacturing companies producing western pharmaceuticals and quasi-pharmaceuticals such as medicated balms and oils. SPMC is the founder of APC, a confederation of ASEAN pharmaceutical manufacturing associations.
Founded in 2003, SPTO represents a group of local companies dealing with the manufacture and/or importation, marketing and distribution of pharmaceutical and related products for local and export markets.
Early 2020, both Singapore Pharmaceutical Manufacturer’s Council (SPMC) and Singapore Pharmaceutical Trade Organisation (SPTO) has been merged into Life Sciences Industry Group (LSIG).
In addition to many local generic pharmaceutical manufacturers and traders, 8 of the world’s 10 biggest pharmaceutical firms also have their manufacturing base in Singapore. Singapore’s pharmaceutical industry employs more than 24,000 people.
In 2019 the pharma industry accounted for 20% of the manufacturing sector which in turn represents about a fifth of Singapore’s gross domestic product. The manufacturers range from API’s to formulations and finished dosage forms, of simple generics to complex biologics and biosimilars.
As a result of all of these years of growth and expertise, the Singapore Government aims to make pharma the fourth largest pillar amongst all industries.
|Name of Committee Member||LSIG Title||Member Company Name|
|Mr Mohan Kumar||Chairman||Strides Pharma Global Pte Ltd|
|Mr Adam Hamid||Deputy Chairman||Naina Mohamed & Sons Pte Ltd|
|Dr Farshad Shishehchian||Committee Member||Blue Aqua International Ltd|
|Dr Stephen Hsu||Committee Member||Boehringer Ingelheim Singapore Pte Ltd|
|Mr Raymond Lam||Committee Member||Pharmaforte Singapore Pte Ltd|
|Dr Ameet Ambarkhane||Committee Member||Covate Pharma Pte Ltd|
|Mr Lee Loh Meng||Committee Member||Sunward Pharmaceutical Pte Ltd|
|Mr Sandeep R Lavalekar||Committee Member||Strides Pharma Global Pte Ltd|
For information or enquires on LSIG, contact:
LSIG Secretariat: Ms Valerie Tan
Office DID: 6826 3147
Email us via our contact us form.